कंपनी का अवलोकन
Caring Brands, Inc. is a wellness consumer products company that specializes in providing over-the-counter and cosmetic solutions to address specific dermatological and hair health concerns. The firm operates within the broader Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on non-prescription pharmaceuticals and topical treatments rather than systemic therapies. The company's current market capitalization stands at $17.24M, while its trailing twelve-month revenue is recorded at $4,215, and employee count data is unavailable in the provided records. These valuation and revenue figures indicate that Caring Brands, Inc. is a micro-cap entity with a relatively small market footprint compared to large-cap pharmaceutical peers, suggesting limited scale in terms of production capacity and distribution reach. The extremely low market cap relative to its revenue generates a unique position in the market, reflecting a small-cap status that often carries higher risk but potentially higher growth potential if product adoption accelerates. The absence of reported employee data further characterizes the organization's lean operational structure typical of small-cap specialty manufacturers focusing on niche product lines.
वित्तीय स्वास्थ्य
The company reports a trailing twelve-month revenue of $4,215, yet it records a net income of -$6,278,191, revealing a severe disconnect where operational costs and losses far exceed total revenue generation. This substantial gap between revenue and net income indicates a highly leveraged cost structure where fixed expenses or significant impairment charges are consuming capital far beyond the inflow from sales. The EBITDA stands at -$3,085,025, highlighting that even before interest and tax adjustments, the core business operations are generating negative cash earnings. Free cash flow is reported at -$670,666, which signifies that the company is currently burning cash rather than generating liquidity, thereby reducing its financial flexibility to fund operations or invest in research without external financing. Gross margin is calculated at 55.6%, which suggests a healthy pricing power on its product lines, but the operating margin of -326658.1% and profit margin of 0.0% demonstrate that overhead costs and general expenses are disproportionately high relative to sales. The balance sheet shows cash holdings of $2.19M against a debt load of $58,650, resulting in a debt-to-equity ratio of 2.80, which implies a leveraged capital structure where equity is used significantly less than debt to finance assets. Despite the high debt-to-equity ratio, the current ratio of 13.16 indicates strong short-term liquidity, suggesting the company has ample current assets to cover its current liabilities. However, the return on equity is -217.1% and return on assets is -68.2%, revealing that management effectiveness is currently negative as the company destroys shareholder value and fails to generate returns on its asset base.
मूल्यांकन आकलन
Trailing P/E and forward P/E ratios are unavailable (N/A) due to the lack of positive earnings, which implies that traditional earnings-based valuation models cannot be applied to assess the expected earnings trajectory at this time. The price-to-book ratio is 8.24, indicating that the market values the company's equity at more than eight times its net asset book value, suggesting a significant market premium or speculative pricing over tangible book value. The price-to-sales ratio is exceptionally high at 4090.68, while the EV/EBITDA stands at -3.99, which together suggest that the market is pricing in substantial future recovery potential or is valuing the company based on asset backing rather than current profitability metrics. The 52-week high is $1.65 and the 52-week low is $0.71, meaning the stock trades within a wide range reflecting high volatility and uncertainty regarding its intrinsic value. The beta value is unavailable (N/A), preventing a direct comparison of price volatility relative to the broader market, but the wide spread between the high and low prices inherently suggests that the stock price is highly sensitive to market sentiment and news flows. Investors analyzing the valuation must rely heavily on the price-to-book metric since earnings-based multiples are currently meaningless given the negative net income and EBITDA figures.
Growth & Income
Revenue growth year-over-year is -9.7%, while earnings growth is unavailable (N/A), indicating that the company is currently contracting in terms of top-line sales rather than expanding its market share. Since earnings are negative and unavailable for growth comparison, the implication is that the company is struggling to stabilize its financial performance before it can achieve growth in profitability. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means it reinvests all available resources into maintaining operations rather than returning capital to shareholders. This non-dividend status is consistent with a firm that is burning cash and requires capital retention to address its negative free cash flow and operational losses. The overall growth and income profile is characterized by negative revenue expansion, zero income generation, and a reliance on cash reserves to fund operations until profitability is restored.